Eytan Abraham

Eytan Abraham currently serves as the Chief Commercial and Technology Officer at Minaris Advanced Therapies since January 2025 and holds a Board Member position at Noga Therapeutics from January 2021. Previously, Eytan Abraham was a Board Observer at CTMC, a joint venture between Resilience and MD Anderson Cancer Center, from January 2024 to January 2025, and served as VP and Business Head of Cell, Gene and Nucleic Acids Franchises at Resilience from September 2021 to January 2025. Eytan Abraham also held a Board Member role at Cellevolve from December 2021 to August 2023. Eytan Abraham completed a post doctorate in Tissue Engineering and Cell Therapy at Harvard Medical School from January 2008 to December 2010 and earned a degree in Finance for Executives from INSEAD in 2017.